Disease workspace

Multiple Myeloma

Plasma cell malignancy characterized by bone lesions, anemia, and renal impairment.

Unmet need

Relapsed/refractory disease options and combination strategies.

B-cell / plasma cellAngiogenesisBone microenvironment

Evidence behind this

Confidence score96%

Signal strength: HighLevel 1 (RCT + regulatory approval)

Evidence grade

Approved

Improved response rates and survival in combination regimens; REMS mandated.

Mechanism

Cereblon-dependent degradation of IKZF1/3 disrupts myeloma cell survival signaling.

clinical trialfda labelPhase III

Authoritative sources

PubMed · 11752346
Thalidomide for refractory myeloma
Singhal S et al. (1999)
View
PubMed · 19717844
Lenalidomide and dexamethasone vs dexamethasone alone
Dimopoulos MA et al. (2009)
View
ClinicalTrials.gov · NCT00029429
Thalidomide in multiple myeloma
View
FDA · 021430
Thalomid FDA approval
View

AI-generated summary

Generated March 15, 2026Last verified June 20, 2026

Thalidomide plus dexamethasone demonstrated significant activity in relapsed myeloma, leading to FDA approval. REMS requirements reflect teratogenicity risk. Strong approved repurposing case.

Source papers

Singhal S et al., 1999
Dimopoulos MA et al., 2009

This summary is AI-assisted and human-reviewed. It does not constitute medical advice. Always consult authoritative sources and qualified professionals.